Preferred Label : Autologous Anti-HER2-CAR-4-1BB-CD3zeta-CD19t -expressing Tcm-enriched T-lymphocytes;
NCIt synonyms : Autologous Memory Enriched HER2(EQ)BBzeta/CD19t -expressing T-cells; Autologous HER2(EQ) BBz/CD19t Tcm Cells;
NCIt definition : A preparation of genetically modified autologous central memory (Tcm) enriched T-cells
transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting
of an anti-human epidermal growth factor receptor 2 (HER2) single chain variable fragment
(scFv) derived from trastuzumab, with a 4-1BB (CD137) costimulatory domain that is
linked to the signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta)
(BBz), and truncated CD19 (CD19t), with potential immunostimulatory and antineoplastic
activities. Upon intravenous infusion, Anti-HER2-CAR-4-1BB-CD19t -expressing Tcm-enriched
T-lymphocytes are directed against HER2-expressing cells, thereby inducing selective
toxicity in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase, is mutated
or overexpressed in many tumor cell types, plays a significant role in tumor cell
proliferation and tumor vascularization. The BBz costimulatory signaling domain enhances
proliferation of T-cells and antitumor activity, while CD19t, a marker for transduction,
is utilized to calculate CAR T-cell dosing and for CAR-expressing cell tracking. Tcm
cells have the capacity for long-lived persistence and retain their ability to proliferate
upon antigen re-encounter. The immunoglobulin G4 (IgG4) extracellular spacer contains
a double mutation, (L235E;N297Q) (EQ) within the CH2 region to reduce Fc receptor
recognition.;
NCI Metathesaurus CUI : CL555282;
Origin ID : C154281;
UMLS CUI : C4727554;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
